Startup Gamma Medica is aiming to improve the odds and lower the cost of effective imaging of dense breast tissue with its molecular breast imaging tool. Now, it's gained a cash infusion of $11.5 million to aid in its commercialization efforts.
U.K.-based Enigma Diagnostics inked a deal with a Chinese biotech outfit and roped in $50 million to support development of its innovative molecular diagnostic system and gain headway in the country's rapidly growing med tech market.
St. Louis, MO-based Veran Medical closed a $12 million financing round. The company, specializing in thoracic navigation an biopsy for early detection of lung cancer, will use the funds toward continued commercial expansion in the U.S. and international launch of the Veran Thoracic Navigation System.
Preimplantation genetic screening and diagnostics provider Reprogenetics is partnering with Illumina to use its next-generation sequencing tech in its analysis of embryos and infertility.
Minnesota's Mayo Clinic is suing one of its former top executives for misappropriation of trade secrets as part of a plan to work for competitor Quest Diagnostics following a false retirement.
Researchers have identified a hormone that is associated with fructose, fibroblast growth factor 21 (FGF21), which increases rapidly in the blood after fructose ingestion. High FGF21 levels in the blood are associated with obesity, insulin resistance and nonalcoholic fatty liver disease in both humans and animals.
Sarasota, FL's RPS Diagnostics, maker of point-of-care diagnostic tests for eye conditions, announced Oct. 13 that it has closed a $28 million debt financing with healthcare-focused investment firm OrbiMed.
NanoString Technologies is teaming up with Brigham and Women's Hospital to study genomic biomarkers and develop diagnostic tests for cancer, furthering the company's plans for accelerated growth.
Medical retinal imaging player Optos, the U.K. National Health Service and academics will participate in a £10 million ($16 million) collaboration to enable earlier detection of eye diseases that threaten vision.
The National Cancer Institute has launched a three to four year broad-based study of exceptional responders--patients who have had particularly good outcomes on cancer therapies as compared to their peers. The initiative was first considered a few years ago when it started to become easier to determine the molecular basis of why a particular patient's cancer responds to a molecularly targeted drug, but it is only being undertaken now.